Zealand Scraps Potential Obesity Drug, Citing Crowded Market
Zealand Pharma A/S is halting development of a potential next-generation obesity medicine after concluding the market has become too crowded for it to stand out.
By Sanne Wass, Naomi Kresge · Bloomberg
Zealand Pharma A/S is halting development of a potential next-generation obesity medicine after concluding the market has become too crowded for it to stand out.